Insmed Inc (INSM)

[windyducat]

zake,

I agree...I listened in and was impressed with the responses. They will vigoroulsy appeal the 414 patent on invalidity. The 151 and the other patent because the expire in 2010 will have lessor impact on the bottom line.

The 414 is manufacturing of IGF regardless of indication.

I like their commitment to staying focused on their business plan which is to 1) staying with Iplex for short-stature in the US 2) pursue manufacturing of Iplex in Europe along with indication approval including Short Stature, 3) new indictation for Iplex, and 4) development of new drugs.

Clearly they were dispointed in the judgement, but they were not shaken and will adapt and fight!